Literature DB >> 1331531

The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.

A L Lear1, M Rowe, M G Kurilla, S Lee, S Henderson, E Kieff, A B Rickinson.   

Abstract

In Epstein-Barr virus (EBV)-positive Burkitt's lymphoma cell lines exhibiting the latency I form of infection (i.e., EBV nuclear antigen 1 [EBNA1] positive in the absence of other latent proteins), the EBNA1 mRNA has a unique BamHI Q/U/K splice structure and is expressed from a novel promoter, Fp, located near the BamHI FQ boundary. This contrasts with the situation in EBV-transformed lymphoblastoid cell lines (LCLs) exhibiting the latency III form of infection (i.e., positive for all latent proteins), in which transcription from the upstream Cp or Wp promoters is the principal source of EBNA mRNAs. We carried out cDNA amplifications with oligonucleotide primer-probe combinations to determine whether Fp is ever active in an LCL environment. The results clearly showed that some LCLs express a Q/U/K-spliced EBNA1 mRNA in addition to the expected Cp/Wp-initiated transcripts; this seemed inconsistent with the concept of Cp/Wp and Fp as mutually exclusive promoters. Here we show that Fp is indeed silent in latency III cells but is activated at an early stage following the switch from latency III into the virus lytic cycle. Four pieces of evidence support this conclusion: (i) examples of coincident Cp/Wp and Fp usage in LCLs are restricted to those lines in which a small subpopulation of cells have spontaneously entered the lytic cycle; (ii) transcripts initiating from Fp can readily be demonstrated in spontaneously productive lines by S1 nuclease protection; (iii) the presence of Fp-initiated transcripts is not affected by acyclovir blockade of the late lytic cycle; and (iv) infection of latently infected LCLs with a recombinant vaccinia virus encoding the EBV immediate-early protein BZLF1, a transcriptional transactivator which normally initiates the lytic cycle, results in the appearance of the diagnostic Q/U/K-spliced transcripts.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1331531      PMCID: PMC240454     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Transcription of the Epstein-Barr virus gene EBNA-1 from different promoters in nasopharyngeal carcinoma and B-lymphoblastoid cells.

Authors:  P R Smith; B E Griffin
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

2.  The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle.

Authors:  C M Rooney; D T Rowe; T Ragot; P J Farrell
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

3.  The Epstein-Barr virus (EBV) early protein EB2 is a posttranscriptional activator expressed under the control of EBV transcription factors EB1 and R.

Authors:  M Buisson; E Manet; M C Trescol-Biemont; H Gruffat; B Durand; A Sergeant
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

4.  Two related Epstein-Barr virus membrane proteins are encoded by separate genes.

Authors:  J Sample; D Liebowitz; E Kieff
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

5.  The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters.

Authors:  S Kenney; J Kamine; E Holley-Guthrie; J C Lin; E C Mar; J Pagano
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

6.  Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers.

Authors:  Q Y Yao; P Ogan; M Rowe; M Wood; A B Rickinson
Journal:  Int J Cancer       Date:  1989-01-15       Impact factor: 7.396

7.  The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner.

Authors:  E A Holley-Guthrie; E B Quinlivan; E C Mar; S Kenney
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

8.  Epstein-Barr virus BZLF1 trans activator induces the promoter of a cellular cognate gene, c-fos.

Authors:  E Flemington; S H Speck
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

9.  Mutually exclusive use of viral promoters in Epstein-Barr virus latently infected lymphocytes.

Authors:  M Woisetschlaeger; J L Strominger; S H Speck
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

10.  Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia.

Authors:  L S Young; R Lau; M Rowe; G Niedobitek; G Packham; F Shanahan; D T Rowe; D Greenspan; J S Greenspan; A B Rickinson; P J Farrell
Journal:  J Virol       Date:  1991-06       Impact factor: 6.549

View more
  37 in total

1.  Expression of EBNA-1 mRNA is regulated by cell cycle during Epstein-Barr virus type I latency.

Authors:  M G Davenport; J S Pagano
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Epstein-barr virus (EBV) nuclear protein 2-induced disruption of EBV latency in the Burkitt's lymphoma cell line Akata: analysis by tetracycline-regulated expression.

Authors:  S Fujiwara; Y Nitadori; H Nakamura; T Nagaishi; Y Ono
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

3.  Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection.

Authors:  Nirojini Sivachandran; Xueqi Wang; Lori Frappier
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

4.  Activity of the EBNA1 promoter associated with lytic replication (Fp) in Epstein-Barr virus associated disorders.

Authors:  A A Brink; C J Meijer; J M Nicholls; J M Middeldorp; A J van den Brule
Journal:  Mol Pathol       Date:  2001-04

5.  Autorepression of Epstein-Barr virus nuclear antigen 1 expression by inhibition of pre-mRNA processing.

Authors:  Mikio Yoshioka; Michelle M Crum; Jeffery T Sample
Journal:  J Virol       Date:  2007-12-12       Impact factor: 5.103

Review 6.  Virus-encoded homologs of cellular interleukin-10 and their control of host immune function.

Authors:  Barry Slobedman; Peter A Barry; Juliet V Spencer; Selmir Avdic; Allison Abendroth
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

7.  Transcription of the Epstein-Barr virus nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene promoter during the initial stages of infection in B cells.

Authors:  S Schlager; S H Speck; M Woisetschläger
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

8.  Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines.

Authors:  B C Schaefer; J L Strominger; S H Speck
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

9.  Kinetics of expression of rhesus monkey rhadinovirus (RRV) and identification and characterization of a polycistronic transcript encoding the RRV Orf50/Rta, RRV R8, and R8.1 genes.

Authors:  Scott M DeWire; Michael A McVoy; Blossom Damania
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Mechanisms that regulate Epstein-Barr virus EBNA-1 gene transcription during restricted latency are conserved among lymphocryptoviruses of Old World primates.

Authors:  I K Ruf; A Moghaddam; F Wang; J Sample
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.